This study is in progress, not accepting new patients
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at UC Davis
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- SHINKEI Therapeutics, Inc
- ID
- NCT06253923
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 45 study participants
- Last Updated